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INTRODUCTION
Eclampsia is a form of Hypertensive encephalopathy with generalised 
convulsions associated with signs of preeclampsia during pregnancy, labour 
(or)  within  7  days  of  delivery  and  not  caused  by  epilepsy  (or)  other 
convulsive  disorders.  It  is  one  of  the  important  causes  of  mortality  and 
morbidity during pregnancy, child birth& puerperium.
Of the estimated 7,00,000 maternal deaths every year world wide 10% 
to 15% are associated with Hypertensive disorders of pregnancy.
The incidence of eclampsia in developing countries is 0.5-2% but 4.9% 
per  10,000  in  United  Kingdom and  1  in  2000  in  Europe  and  developed 
countries.
Eclampsia accounts for 50,000 maternal deaths a year world wide.
The maternal case fatality rate is 1.8% and 35% of eclamptics will have 
one major complication.
Perinatal  mortality  rate  in  developed  countries  is  less  than  10/1000 
births to as high as 80 (or) more/1000 births in developing countries. 
The Collaborative Eclampsia Trial group found that the incidence of 
perinatal  mortality  in  eclampsia  ranges  from  224  to  307/1000  cases  of 
Eclampsia. According to Mudhaliar, perinatal mortality in Eclampsia is 300-
600/1000  cases  of  Eclampsia.  The  overall  PNMR-Eclampsia  is  363/1000 
cases of Eclampsia.
The presence of a toxin, that acts as a pressor substance (hysterotonin) 
in  the  deciduas  and  amniotic  fluid  of  women  has  been  suggested  to  be 
responsible for the multiplicity of clinical expression. To effect a cure, the 
chorionic  villi  must  be  expelled  or  surgically  removed.   Resolution  of 
eclampsia occurs only with delivery and subsequent removal of functioning 
trophoblastic tissue. Accelerated recovery from the disease process following 
delivery  could  avert  associated  serious  and  life  threatening  maternal 
complications  and  shorten  the  time  required  for  intensive  care  and 
hospitalization.   The present  study  evaluates  the effect  of  immediate  post 
partum  curettage  on  the  resolution  of  clinical  and  laboratory  indices 
associated with eclampsia.
AIM OF THE STUDY
 To evaluate the effect of immediate postpartum curettage upon 
maternal recovery from eclampsia.
REVIEW OF LITERATURE
Definition:-
Preeclampsia  complicated  by  generalized  tonic-clonic  convulsions  is 
termed eclampsia. Fatal coma without convulsions also called as eclampsia, 
however it is better to limit the diagnosis to woman with convulsions and to 
regard deaths in non convulsive cases as due to severe preeclampsia.
Depending  on  whether  convulsions  appear  before,  during  (or)  after 
labour, eclampsia is designated as Antepartum, Intrapartum (or) Post partum. 
Etiology:  
Etiology of Pregnancy induced Hypertension.
1)Abnormal trophoblastic Invasion:
In pre eclampsia, there is incomplete trophoblastic invasion of uterine 
spiral  arteries.  Endothelial  damage,  insudation of  plasma constituents  into 
vessel wall, proliferation of myointimal cells &medial necrosis are observed.
Lipid  laden  myointimal  cells  and  macrophages  –  atherosis  causes 
obstruction of spiral arterioles. 
2) Immunological Factors:-
The  risk  of  preeclampsia  is  enhanced  where  formation  of  Blocking 
Antibodies to placental antigenic sites might be impaired. They arise where 
effective immunization by previous pregnancy is lacking as in first pregnancy 
(or) in multiple pregnancy where number of Antigenic sites provided by the 
placenta is great compared to the amount of antibody—Beer(1978)
Bardeguez and associates (1991) –woman who develop preeclampsia 
have lower  proportion of  helper  T cells  (Th1)  than normotensive  woman. 
Th1/Th2 imbalance  with  Th2  dominance  may  be  mediated  by  adenosine, 
which is higher in serum of preeclampsia woman than normotensives.
Preeclampsia  common  in  woman  with  anticardiolipin  antibodies, 
Antibodies associated with b2 glycoprotein 1 appear more relevant. Immune 
complexes and anti endothelial cell antibodies may also be involved. (Taylor 
and Roberts,1999)
3)Genetic Factors:-
Ness (2003) suggested that the tendency for preeclampsia is inherited. 
Cooper and Liston (1979) suggested that susceptibility to pregnancy induced 
Hypertension  is  due  to  single  recessive  gene Chesley  and  Cooper  (1986) 
suggested single gene model.   Trogstad and coworkders  (2004) suggested 
polygenic inheritance. Kilpatrick and associates (1989) showed association 
between HLA-DR4 and proteinuric Hypertension. 
Ward  and  Zhang  (2003)  reported  that  woman  heterozygous  for 
angiotensinogen gene variant T235 had a higher incidence of preeclampsia of 
fetal growth restriction. Morgan and colleagues (1995,1999) did not confirm 
this, but they found that woman homozygous for the mutation had abnormal 
trophoblastic invasion.
Polymorphisms of genes for TNF, Lymphotoxin-a and inteleukin –1b 
have  been  studied  with  varying  results  (Helfer;  Kacgneuher;  Livingstor 
2001).  Dizon Townsend  and colleagues  (1996)  found higher  incidence  of 
factorV leiden mutations in pregnancy induced hypertensive woman.
4) Nutritional factors:-
A number of dietary deficiencies (or)  excess have been blamed as a 
cause of eclampsia. Dietary taboos included are meat, protein, purines, fat, 
dairy products, salt and others.
John  and  coworkers  (2002)  showed  that  a  diet  rich  in  fruits  and 
vegetables have antioxidant activity with decreased blood pressure.
Zhang and associates showed that the incidence of preeclampsia was 
doubled in Woman whose daily intake of ascorbic acid was less than 85mg.
Carroli and colleagues (1994) implicated that calcium supplementation 
reduces the risk of preeclampsia.
Belizan91991),Lopez-Jeramillo (1989), Sanchez-Ramos(1194) and their 
associates reported that mid pregnancy daily dietary supplementation of 2gm 
calcium significantly reduced the incidence of Hypertension.
5)Vasculopathy and the inflammatory Changes:-
In response to placental factors released by ischemic changes, (or) any 
other  inciting  cause,  a  cascade  of  events  is  set  in  motion  (Redman  and 
Sargent 2003)
Staff and colleagues 1999 - suggested that the decidua also contains an 
abundance of cells when activated, can release noxious agents. They serve as 
mediators to provoke endothelial cell injury.
Fass and colleagues 2000 and Gervasi 2001, showed that preeclampsia 
is due to an extreme state of activated leucocytes in maternal circulation.
TNF- α and their  interleukins may contribute to the Oxidative stress 
associated with preeclampsia.
Oxidative  stress  produce highly  toxic  radicals  and injure  endothelial 
cells(Manten and associates 2005) modify their nitric oxide production and 
interfere with prostaglandin balance.
PATHOGENESIS
1) Vasopasm:
The concept of vasopasm was advanced by volhard (1918) based on 
direct  observation  of  small  vessels  in  nail  beds,  ocular  fundi  and  bulbar 
conjunctiva.  Wang  and  colleagues  (2002)  demonstrated  disruption  of 
endothelial junctional proteins. Suzuki and co workers (2003) demonstrated 
ultra  structural  changes  in  sub endothelial  region of  resistance  arteries  in 
preeclamptic woman. Vasospasm may be worse in HELLP syndrome-Fischer 
and colleagues, 2000.  
2) Endothelial cell activation:-
Hayman,  Roberts,  Walker  2000  showed  that  clinical  syndrome  of 
preeclampsia result from widespread endothelial cell changes.
(i) Increased Pressor responses:-
Abdul—Karim and Assali 1966 showed that normal pregnant woman 
develop refractoriness to infused Vasopressors.
Woman with early preeclampsia, have increased vascular reactivity to 
infused  nor  epinephrine  and  angiotensin  II.  (Raab  and  co  workers  1956. 
Talledo and associates, 1968)
ii) Prostaglandins:-
Taylor  and  Roberts  (1999)  showed  that  endothelial  prostacyclin 
production is decreased in preeclampsia that is mediated by phospholipase 
A2.
Platelet thromboxane A2 increases and the prostacyclin: thromboxane 
A2 ratio decreases. That favours increased sensitivity to angiotensin II that 
ends in Vaso constriction.
Chavarria (2003) given the evidence that these changes are apparent as 
early as 22 weeks in woman who later develop preeclampsia.
iii) Nitric Oxide:
A potent vasodilator synthesized from L-arginine by endothelial cells. It 
is the compound that maintains normal low pressure vasodilator state 
characteristic of Feto placental perfusion-Myatt and co workers 1992.
Wang  and  colleagues  showed  that  preeclampsia  is  associated  with 
decreased endothelial nitric oxide synthase expression, which increases cell 
permeability. It’s production increased as compensatory mechanism in severe 
preeclampsia. So increased serum concentration of nitric oxide is likely the 
result of hypertension, not the cause – Morris and colleagues 1996.
iv) Endothelins:
Mastrogiannis and coworkers showed that these 21 amino acid peptides 
are  potent  vaso  constrictors,  and  endothelin  -1  (ET-I)  is  primary  isoform 
produced by human endothelium. 
Taylor and Roberts (1999) showed that the placenta is not the source of 
increased ET-I.
Sagsoz and Kucukozkan 2003 observed that treatment of preeclamptic 
woman with magnesium sulphate lowers ET-I concentrations. 
v) Angiogenic Factors:
Vascular endothelial growth factor (VEGF) and placental growth factor 
(PIGF),  the  glycosylated  Glycoproteins  are  selectively  mitogenic  to 
endothelial cells.
Simmons and co workers 2000 showed the VEGF is increased in serum 
from woman with preeclampsia but the bioavailability is decreased.
In  Preeclampsia,  the  gene  for  Soluable  Fms-Like  tynosine  kinase  1 
(SFLt) is upregulated –Maynard &associates. 
PATHOPHYSIOLOGY
Maternal Vascular 
Disease Excessive trophoblastFaulty Placentation
Genetic, Immunologic 
Inflammatory factor
Reduced uteroplacental Perfusion
Vasoactive agents 
Prostaglandins
Nitric Oxide 
Endothelins
Noxious agents 
Cytokines
Lipid peroxide
Clinical Course of eclampsia
Eclampsia is most common in last trimester and becomes more frequent 
as term approaches.
Maternal hypoxia and lactic acidosis caused by convulsions, the fetus 
develops  bradycardia,  pulmonary  edema may occur.  Sudden death  due  to 
massive cerebral hemorrhage can occur. 10% of cases had blindness due to 
retinal detachment (or) occipital lobe ischemia and edema. Rarely eclampsia 
is followed by psychosis.
Endothelial 
Activation
Vasospasm Capillary leak Activation of coagulation
Hypertension Oliguria
Seizures Abruption
Thrombo 
cytopenia
ProteinuriaEdema
Hemo 
concentration
Liver 
ischemia
Differential diagnosis:-
Epilepsy,  encephalitis,  meningitis,  cerebral  tumor,  cysticercosis  and 
ruptured cerebral aneurysm.
Complications of Eclampsia:
Placental  abruptions  (10%),  Neurological  deficits  (7%)  Aspiration 
pneumonia (7%) pulmonary edema (5%) cardiopulmonary arrest (4%) Acute 
renal failure (4%) maternal death (1%).
MANAGEMENT
1.General management
It plays an important role in the management of eclampsia. The patient 
is nursed in a quiet room with a medical or nursing attendant always present. 
Pulse rate, respiration, blood pressure, colour, restlessness, urine output must 
be  constantly  observed.  A mouth  gag,  airway  and  O2 must  be  available. 
Patient  is  put  in  left  lateral  position  in  a  railed  cot.  Throat  is  cleared  of 
secretions  and  vomitus  by  intermittent  suction.  A  soft  firm  mouth  gag 
introduced in time will save injury to the tongue. An indwelling catheter in 
the bladder will give an accurate assessment of the urine output and will also 
prevent restlessness due to a full bladder (Dewhurst 1984.) Blood pressure is 
measured half hourly till it is controlled and then second hourly. A record of 
grade of consciousness is maintained. Nutrition and hydration are maintained 
parenterally.
II. Anticonvulsant line of Management
History
In  the  early  years  of  the  20th century  early  intervention  to  achieve 
delivery was widely practiced. The mortality was very high. Later in 1930, 
Strongonoff  introduced  his  conservative  regimen  of  heavy  sedation  with 
morphia by injection, and chloral or bromide per rectum gave better results. 
Once the convulsions were fully controlled the membrane were ruptured.
In 1920-30 stomach and colonic lavage with magnesium sulphate was 
used to clear the patient of toxins and sedation with chloroform.
In  1951-1960  barbiturates  were  used.  ‘O’  Donnel  Browned  used 
continuous  thiopentone  in  20%  dextrose,  but  causes  marked  cerebral 
depression.
In  1961,  lytic  cocktail  regimen using  pethidine,  chlorpromazine  and 
promathazine was introduced by Dr. M.K.K.Menon. He treated 1448 cases. 
Recurrence of fits was 15%. Maternal mortality was 2.4%.
Nager  et  al  (1988)  treated  98  cases  with  lytic  cocktail  (LC)  with 
maternal mortality rate of 8.2%.
Llewellyn Jones (1961) conducted a study on 150 cases of eclampsia 
with lytilcocktail and the maternal mortality was 6.6%.
Lopez  Liera  used  lyticocktail  on  120  eclmaptic  women  and  the 
maternal mortality was 11.7%.
Lean et al (1968) have reported excellent results with large doses of 
chlordiazepoxide or diazepam.
Magnesium  sulphate  was  first  used  by  Horn  in  Germany  in  1906 
intrathecally.  In  1926  intravenous  regimen  of  magnesium  sulphate  was 
reported by Lazard in Los Angeles and intramuscular regimen by Dorsett in 
St.  Louis.  However  the  popular  intra  muscular  regimen of  Pritchard  was 
introduced in  1955 and intravenous regimen by Zuspan in 1964.
Phenytoin  Sodium  was  introduced  in  management  of  eclampsia  in 
1987.
DOSAGE SCHEDULE OF VARIOUS REGIMENS 
1. Menon’s Regimen (1961)
0 Hours
25 mg chlorpromazine and 100 mg pethidine in 20 ml of 5% glucose 
given intravenously. 50 mg chlorpromazine and 25 mg promethazine given 
intramuscularly.
A drip of 20% dextrose containing 200 mg pethidine is set up and run 
slowly at a rate of 20-30 drops/minute.
0-4 hrs Promethazine 25 mg Im
0-8 hrs Chlorpromazine 50 mg Im
0-12 hrs Promethazine 25 mgIm
0-16 hrs Chlorpromazine 50 mg Im
0-20 hrs Promethazine 25 mg Im
0-24 hrs Chlorpromazine 50 mg Im
0-28 hrs Promethazine 25 mg Im
0-32 hrs Chlorpromazine 50 mg Im
0-36 hrs Promethazine 25 mg Im
0-40 hrs Chlorpromazine 50 mg Im
0-44 hrs Promethazine 25 mg Im
0-48 hrs Chlorpromazine 50 mg Im
Menon (1961) used lyticocktail in 1448 eclamptic women and maternal 
mortality was 2.2%. 
Llewllyn Jones (1961) in his study using lyticcocktail had a maternal 
mortality of 6.6%. Lopez Liera (1982) in his study had a maternal mortality 
of 11.7%. Bhalla et al (1994) in his study using lyticcocktail had a maternal 
mortality of 4.4%. 
2. Diazepam(1968) 
A loading dose of 10 mg diazepam intravenously over 2 minutes followed 
by an intravenous infusion of 40 mg in 500 ml normal saline for 24 hours. 
Rate  of  infusion  titrated  against  level  of  consciousness  with  the  aim  of 
keeping the woman sedated but arousable. Diazepam can cause respiratory 
depression. It is poorly excreted by the neonate which tends to be sedated, 
hypothermic and unable to breast feed for several days.
3. Chlordiazepoxide (1968)
An initial intravenous injection of 10 mg followed by a continous injection 
of 100 mg in 500 ml of 5% dextrose at a rate of 30 drops/ minute or titrated 
according to the sedation needed.
4. Clonazepam (1977)
1 mg intra venous bolus followed by an intravenous infusion of 2.5mg in 
500 ml of 5% dextrose.
5. Chlormethiazole (Duffs et al 1968)
It   is  an  effective  anticonvulsant.  Intra  venous  infusion  of  0.8% 
chlormethiazone in 500 ml of 5% dextrose at a rate of 2-4 gm/hours for first 
5-10 minutes and 0.5-1 gm/hour thereafter to produce easily arousable sleep. 
It has a short half life of 45 minutes, so does not produce prolonged sedation 
in the mother or neonate.
6. Magnesium Sulphate (MgSo4)
In 1955 Prichard initiated a standardized treatment regimen at Parkland 
Hospital.
In 1964 Zuspan initiated the intravenous magnesium sulphate regimen.
a) Pritchard Regimen
Loading Dose Maintenance Dose
4 g of 20% MgSo4 IV at a rate of 
exceeding 1 g/ min
Every 4 hrs 5 gm of 50% MgSo4 
as  IM on alternate  buttocks  after 
assuring
10 g of  50% MgSo4 deep IM in 
buttocks
a) Patellar reflex is present 
b)  Respiration  are  not  depressed 
>16/ minute
c)   Urine  output  >  100  ml  in 
preceding 4 hours
If  convulsions  persists  after  15 
minutes, give 2 g of 20% MgSo4 
at  a  rate  not  exceeding  1  gm/ 
minute
MgSo4 discontinued 24 hours after 
delivery
b) Zuspan’s Regimen (1964)
Loading Due Maintenance Dose
4 g of 20% MgSo4 IV at a rate not 
exceeding 1g /min
1-2 g /hour by controlled infusion 
pump for  24 hours after  delivery 
(concentration not to exceed 20%)
c) University of Tennessee guidelines for intravenous mgso4
Loading Dose 
Give 30ml of 20% mgso4 solution (6g) in 100ml of 5% dextrose over 
10 to 15 minutes.
Maintenance Dose:
Add 20g of mgso4 (Four 10 ml ampoules of 50% solution to 1000ml 
of 5% Dextrose and give intravenously at a rate of 100ml/hour (2g/hour0. 
Adjust the rate of infusion to keep serum magnesium levels between 4.8 & 
9.6 mg/dl.
If  serum  magnesium  levels  are  available  the  dose  is  adjusted 
according to the patellar reflex and urine output in previous 4 hour period.
Monitoring of Magnesium Toxicity:
• Urine output atleast 30ml/hour
• Deep tendon reflexes should be present.
• Respiratory rate should exceed 14/min.
PHARMACOKINETICS
Magnesium Sulphate
It  has  a  molecular  weight  of 246.  1 gm of magnesium sulphate  has 
98mg of elemental magnesium.
Distribution and Plasma levels 
Infused magnesium sulphate is distributed rapidly throughout the entire 
extra cellular fluid space and some is taken up by bone but none by red blood 
cells.  Intravenous  loading  due  of  4-6  gm  results  in  immediate  plasma 
concentration of 5-9mg/dl and it falls to 3-4mg/dl in 60 minutes. Within 90 
minutes 50% of infused magnesium moves into bones and other cells.  By 
4hours 50% of infused Magnesium is excreted in the urine.
Excretion
Magnesium  is  excreted  almost  solely  by  the  Kidneys.  50%  of  the 
infused dose is excreted after 4 hours in urine. 99% of the bolus intravenous 
dose is excreted within 24hours.
Mechanism of action
Some believe its action to be mainly peripheral at the neuro muscular 
junction  with  minimal  central  effects.  While  some  believe  that  the  main 
action  is  central.  Calcium  entry  into  neurons  is  regulated  by  specific 
excitatory amino acid linked channels.  Excitatory  amino acids such as L-
glutamate and L-aspartate  are  the major  neuro transmitters  in  mammalian 
central  nervous  system.  These  neurotransmitters  produce  their  effects  by 
interacting with certain receptors on the cell  surface, the excitatory amino 
acid  receptors,  N-methyl  D-aspartate  (NMDA)  is  the  best  characterized 
excitatory  amino  acid  receptor  sub  type.  NMDA receptor  has  its  channel 
blocked by magnesium ion and thus blocking neuronal calcium influx. Thus 
magnesium  has  a  central  nervous  system  effect  in  blocking  the  seizure. 
Cotton and associates (1992)9 have shown that hippocampal seizures could 
be blocked by magnesium 
Magnesium  sulphate  is  a  potent  vasodilator  especially  in  cerebral 
vasculature thus relieving cerebral vasospasm which is thought to be a cause 
for eclampsia.
Other Actions
 Vaso dilatation in Vascular beds
 Increased uterine blood flow (Harbert&collegues)
 Increased renal blood flow
 Increased  prostocyclin  release  by  endothelial  cells  (Watson  and 
Colleagues)
 Decreased plasma rennin activity
 Decreased angiotensin converting enzyme levels
 Attentuation of vascular response to pressor substances
 Bronchodilatation
 Reduced platelet aggregation
Pharmacological effects
 Anti convulsant action
 Transient hypotensive effect
 Transient but mild decrease in frequency of uterine contractions but no 
change in the intensity of contractions.
 Clinically insignificant decrease in short term variability of fetal heart 
rate
 No change in long term variability of fetal heart rate or fetal heart rate 
accelerations
Side Effects
First sign of magnesium toxicity is usually the loss of patellar reflexes 
that  occurs  usually  at  about  9-12mg/dl  because  of  curariform action.  So 
maintenance dose of  MgSO4  is  not  to be given in the absence of patellar 
reflexes.
Early  signs  and  symptoms  of  magnesium  toxicity  include  nausea, 
feeling of warmth, flushing, somnolence, double vision, slurred speech and 
weakness. These symptoms usually develop at plasma levels of 9 to 12mg/dl.
Muscle paralysis and respiratory arrest develop at plasma level of 15-
17mg/dl. Hence respiratory rate is monitored closely.
Cardiac arrest develops at level of 30-35mg/dl. Thus it is important to 
keep an ampoule containing 1 gram of calcium gluconate at the bedside for 
intravenous administration as an antidote in case of magnesium toxicity.
Tracheal  intubation and mechanical  ventilation for severe  respiratory 
depression (or) arrest. There is a transient decrease in uterine activity during 
intravenous injection alone. It can cause a transient decrease in fetal heart 
rate  variability,  neonatal  neuro  muscular  and  respiratory  depression 
hyporeflexia and low apgar scores. These effects were reported in preterm 
infants in association with fetal growth retardation. In addition several recent 
studies reported no ill effects in term infants. It can cause excessive blood 
loss after delivery.
Efficacy and Safety
Rapidly effective, reliable & predictable duration of action, wide safety 
margin,  non depressive  and non toxic  to  the  mother  and baby,  simple  to 
administer and monitor in the clinical setting and readily available antidote. 
Serum magnesium can be measured to ensure therapeutic concentration but 
many practitioners are happy to omit biochemical monitoring because of its 
wide margin of safety.
Duley  et  al  (1995)  in  his  study  used  clinical  evaluation  alone  and 
showed  that  the  there  is  no  need  to  check  serum  magnesium  levels. 
Estimation of magnesium levels are useful in the management of treatment 
failures.
Drug interactions with Magnesium Sulphate
Agent Effect Recommendation
Depolarising / non
Depolarizing neuro 
Muscular blockers
Increased activity of 
These agents
May  need  dosage 
reduction  of  neuro 
muscular blocking agents
CNS depressants eg
opioids,  barbiturates, 
general anaesthetics
Additive CNS
Depression
May  require  dose 
reduction  of  CNS 
depressants
Nifedipine Hypotension Administer  with  caution 
and  adjust  nifedipine 
dosage if necessary
At the  neuromuscular  junction magnesium decreases  the  presynaptic 
release  of  acetylcholine  and reduces  the  sensitivity  of  the  post  junctional 
membrane(motor end plate). Ghoneim and long reported that the action of 
succinylcholine  (non  depolarizing  agent)are  potentiated  by  magnesium 
sulphate.  A single  dose  of  succinycholine  can be  safely  used to  facilitate 
tracheal intubation but may not apply when repeated dose of succinyl choline 
are used.
When a patient is simulataneously exposed to magnesium sulphate and 
nifedipine some interaction might be expected as both are calcium channel 
blockers. Fenakel et al (1998) studied nifedipine in women who are receiving 
magnesium  sulphate  and  found  effective  blood  pressure  control  in  96% 
women without hypertension. It would appear that while a theoretical risk of 
interaction could exist in practice this is relatively uncommon.
III – Antihypertensives 
Alpha Methyl dopa
This was introduced to treat hypertension in 1960 by sjoderdesma
OH
CH
3
NH
2
COOHC
CH3
OH
Pharmacological action
After  oral  (or)  intravenous  administration  the  hypotensive  effect 
appears after 3 to 6 hours and 1-2 hours respectively. Hypotensive effect is 
associated with reduced cardiac output and total peripheral resistance. It does 
not reduce renal blood flow.
Mechanism of action
1. Inhibits adrenergic receptors in the vasomotor center
2. Inhibits rennin release by the kidneys
Absorption and Excretion
It is well absorbed orally and completely excreted in urine in 12 hours.
Adverse Effects
It  commonly  produces  sedation,  headache  and  fatigue.  Other  side 
effects  are  diminished  Intellectual  drive,  drowsiness,  forgetfulness, 
nightmares,  parkinsonism,  lactation  and  depression.  Tolerance  to 
antihypertensive  effect  is  common.  It  can  cause  drug  fever,  altered  liver 
function  test  (or)  cholestatic  jaundice.  Rarely  agranulocytosis, 
thrombocytopenia, gastrointestinal tract upset, constipation and skin rashes.
Nifedipine
It a calcium blocker, introduced in clinical practice in 1970 by Flerk, 
and Entus in 1971.
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PHARMACOLOGICAL ACTIONS
It blocks the calcium transport through voltage dependent channel and 
thus  inhibits  the  entry  of  extra  cellular  calcium  ion  necessary  for  the 
excitation  contraction  coupling  in  both  the  skeletal  muscle  and  smooth 
muscle.  It  has  a  negative  inotropic  action  on  heart,  relaxes  the  vascular 
smooth muscle in systemic as well as pulmonary circulation. Thus decreases 
the vascular resistance and the blood pressure. If causes a reflex tachycardia. 
It can be used orally or sublingually.
Side effects
It  produces  headache,  tachycardia,  dizziness,  fatigue,  orthostatic 
hypotension, leg cramps and skin rashes.
Interactions
Some  have  advised  caution  while  using  nifedipine  with  magnesium 
sulphate as both are calcium channel blockers, which may have a depressive 
effect on blood pressure.
Fenakel et al(1998) studied nifedipine in women who were receiving 
magnesium  sulphate  and  found  effective  blood  pressure  control  in  96% 
women  without  undesirable  side  effects  and  no  cases  of  hypotension.  It 
would therefore appear that while a theoretical risk of interaction does exist. 
In practice this is uncommon.
Bhalla et al (1994) in his study used nifedipine and magnesium sulphate 
and had a good control of blood pressure.
Other Antihypertensives
Intravenous hydrallizine (or) intravenous labetalol produces remarkably 
effective control of the high blood pressure.
OBSTETRIC MANAGEMENT
After stabilizing the patient a detailed obstetric examination  made. If 
she is in labour, amniotomy done and oxytocin infusion started. If she is not 
in labour, induction with prostaglandin E2 gel done for a favourable cervical 
score. Cesarean  section  done  for  obstetric  indication  or  for  failure  of 
medical treatment.
I stage  :
During labour fetal heart rate ausculated every fifteen minutes, blood 
pressure  recorded  every  2nd hourly.  Intake,  output  maintained  strictly. 
Maternal  pulse  recorded  hourly.  Cardiovascular  system  and  respiratory 
system  ausculated  every  2nd hourly.  Intravenous  fluids  preferably  Ringer 
lactate  infused at a rate of 1 ml/kg/hour.
II stage  :  Cut short by forceps, if indicated
III stage  :
Prophylactic methyl ergometrine usually avoided to prevent the rise in 
blood pressure.
Blood  pressure  recorded  every  2nd hourly  until  controlled  and  then 
every 4th hourly for 48hours. All other vital signs and urine output  recorded 
every second hourly for 48 hours after delivery.
LABORATORY FINDINGS IN PRE ECLAMPSIA :
The laboratory changes reflect the effects of the pre eclampsia on the 
kidney,  liver  foetoplacental  units  and  in  some  cases,  the  haematological 
elements.
1. Altered Renal function :
In severe pre eclampsia, there are elevation in Serum creatinine, Blood 
urea nitrogen and Uric acid levels as well as decrease in creatinine clearance, 
proteinuria and changes in the urinary sediment.
S.No. Normal Pregnancies Pre eclampsia
1. Sr. Creatinine 0.8 mg/dl or less 1.3 to 1.4 mg/dl
2. Urea 15 mg % 20-25 mg%
3. Creatinine clearance 130 ml / min or 
more
100 ml / min or 
less
There are many postulations that state uric acid elevation is a specific 
laboratory finding in pre eclampsia and uric acid levels normally decreases at 
the beginning of pregnancies, remain low during the second trimester, nearly 
reaching non-pregnant levels at term.  Marked elevation of uric acid, urea and 
creatinine occur only with severe pre eclampsia.
Changes in liver function tests :
Patients  with  severe  pre  eclampsia  show marked  increase  in  SGPT, 
SGOT and LDH.  The raised total LDH is usually reflected in the elevations 
of  isoenzyme 5  (LDH liver).   If  haemolytic  anaemia  is  also  present,  the 
electrophoretic pattern will show elevation of isoenzymes, 1,2 and 5.  After 
delivery, SGPT and SGOT levels rapidly decrease and in most cases reach 
normal levels by the fifth post partum day.  LDH fall more slowly and normal 
values are reached by post partum day eight to ten.
Haematologic Abnormalities :
1. Elevation of haemoglobin and haematocrit caused by characteristic 
decrease in plasma volume.
2. Thrombocytopenia  :   Pritchard  et  al  found  26% of  91  eclamptic 
patients  found to  have  platelet  counts  below 1,50,000.   17% had 
platelet  count  below  1,00,000  and  3%  had  platelet  count  below 
50,000.
3. The plasma fibrinogen concentration is  usually  normal  or  slightly 
increased and it is unusual to find a fibrinogen level below 200 mg% 
unless the clinical course is complicated by abruption placenta.
4. The thrombin time may also be altered in eclampsia patients and it is 
likely to be prolonged in about 50% of these patients with severe 
forms of preeclampsia.  This change is peculiar because it may occur 
in patients with normal fibrinogen concentration and normal level of 
fibrinogen split products.
5. Pre  eclamptic  patients  with  positive  D.  dimer  (>0.5mg%) have  a 
more severe form of the disease than those with a negative test.
HELLP SYNDROME :
It is an acronym proposed by Weinst to describe the clinical condition 
characterized by Hemolytic anaemia, elevated liver enzymes and low platelet 
count.  The criteria for the diagnosis as defined by sibai are :
Haemolysis :
Schistiocytes in the blood smears
Bilirubin > 1.2 ml/dl
Absent plasma haptoglobulin
Elevated liver enzymes :
SGOT > 72 IU / L
SGPT > 600 IU/L
Low platelet count 
Platelet < 100 x 103 / mm3
This condition has to be differentiated from thrombotic thrombocytic 
purpura  (TTP)  because  their  clinical,  laboratory  and  histological 
characteristics  are  similar.   Every  hypertensive  pregnant  patient  with 
haematological  complications  must  be  managed  as  if  the  process  were 
included by pregnancy.  This implies delivery and most cases the patient will 
improve rapidly post partum.
SUBJECTS AND METHODS
The subjects of this study were 50 pregnant women who presented to 
labour  and  delivery  department,  Government  Rajaji  Hospital  in  the  time 
period between January 2007 to September 2007 with physical findings of 
eclampsia.
At  admission,  evaluation  included  mean  arterial  pressure  (MAP), 
haemoglobin,  Urine  –  albumin,  Uric  acid,  quantitative  platelet  count,  Sr. 
creatinine, Liver function tests and examination of the fundus. As a routine 
location of placenta was recorded at antepartum sonography.
25  patients  underwent  uterine  curettage  after  vaginal  or  caesarean 
delivery  immediately  after  delivery  of  placenta  under  sedation  with 
promethazine hydrochloride.  At caesarean, the presumed area of the decidua 
basalis  were  curetted  with large  placenta  curette.   Patients  who delivered 
vaginally were curetted under i.v. sedation using a placenta curette.
All curettage specimens were sent for pathological examination.
During the immediate  puerperium, all  subjects  were observed in  the 
obstetric intensive care unit until disease remission was apparent.  Intensive 
postpartum  surveillance  maintained  for  24  hours  and  included  hourly 
measurement of MAP, hourly urine output, hemoglobin with platelet count, 
uric acid and creatinine assessment at 24 hours. Recurrence of convulsions or 
other complications was noted and duration of stay in the ICU recorded.
All medications given in the obstetric room were recorded.  All women 
with eclampsia and imminent eclampsia received Magnesium sulphate.  None 
of  the  patients  received  fluid  challenge  in  the  recovery  room.  Discharge 
criteria from the area included.
1. Adequate diuresis (output > 100 ml /  hour sustained for atleast  2 
consecutive hours)
2. Blood pressure control with diastolic values below 100 ml Hg and 
systolic below 160 mm hg.
The  information  collected  regarding  all  the  selected  cases  were 
recorded in a Master Chart. Data analysis was done with the help of computer 
using Epidemiological Information Package (EPI 2002).
Using  this  software,  frequencies,  percentage,  range,  mean,  standard 
deviation x2 and  'p' values were calculated. A 'p' value less than 0.05 is taken 
to denote significant relationship. 
RESULTS
A. Profile of cases studied
Table 1 : Age Distribution
Age in 
Years
No of cases in
Group A Group B
No % No %
Less than 20 3 12 2 8
20 – 24 18 72 17 68
25 – 29 1 4 3 12
30 & above 3 12 3 13
Total 25 100 25 100
Mean 22.64 22.96
S.D 4.64 3.96
P 0.3314 (Not Significant)
The  mean  age  of  the  cases  in  both   the  groups  does  not  differ 
significantly. 
70% of the patients belong to age group of 20-24 years
Table : 2 Parity
Parity No of cases in
Group A Group B
No % No %
Primi 18 72 15 60
Multi 7 28 10 40
Total 25 100 25 100
P 0.5505 (Not Significant)
60-72% of the cases are primi gravida, 28-40% of the cases are 
multi gravida
Table 3 : Mode of Delivery
Mode of 
Delivery
No. of cases in
Group A Group B
No % No %
LSCS 5 20 2 8
Vaginal 20 80 23 92
Total 25 100 25 100
P 0.2087 (Not Significant)
Mode of delivery in the two groups does not differ significantly.
In Group A, LSCS rate was 20% and group B, LSCS rate was 8%.
Comparison of  outcome parameters in the two groups 
Table 4 : Mean Arterial Pressure 
MAP at Group A Group B ‘p’
Mean S.D Mean S.D
Admission 118.3 9.6 123.7 11.0 0.0843
(Not 
Significant)
12 hours 103.6 7.2 108.9 5.3 0.005 
(Significant)
24 hours 98.6 6.9 108.9 5.8 0.0001 
(Significant)
MAP of curettage group significantly reduced compared with controls 
at 12 hrs and 24 hrs after delivery
Table 5 : Urine Output
Urine 
output at
Group A Group B
‘p’
Mean S.D Mean S.D
Admission 73.1 17.5 65.8 15.6 0.1817 
(Not 
Significant)
12 hours 90.9 16.6 72.0 12.3 0.0001 
(Significant)
24 hours 95.2 7.7 72.7 14.4 0.0001 
(Significant)
Rate of urine output for the curettage group was significantly more than 
for  the  non  curettage  group  at  4  hr  interval  post  partum.   The  smallest 
difference between both groups was observed at 12 hrs and largest at 24 hrs 
post partum.
Table 6 : Platelet Count
Platelet 
count at
Group A Group B
‘p’
Mean S.D Mean S.D
Admission 1.93 0.42 1.87 0.17 0.4654 
(Not 
Significant)
24 hours 2.03 0.42 1.86 0.17 0.1441 
(Not 
Significant)
The platelet count of the 2 groups does not show significant difference 
after delivery.
Table 7 : Urea
Urea at
Group A Group B
‘p’
Mean S.D Mean S.D
Admission 26.8 9.4 25.9 6.8 0.9612 
(Not 
Significant)
24 hours 24.7 6.1 25.2 6.0 0.7225 
(Not 
Significant)
Table 8 : Creatinine
Creatinine
Group A Group B
‘p’
Mean S.D Mean S.D
Admission 0.94 0.21 1.0 0.16 0.1368 
(Not 
Significant)
24 hours 0.87 0.12 0.91 0.12 0.1427
 (Not 
Significant)
Table 9 : HB %
HB % at
Group A Group B
‘p’
Mean S.D Mean S.D
Admission 8.84 0.4 8.6 0.7 0.1392
(Not Significant)
24 hours 8.25 0.36 8.13 0.3 0.2176 
(Not Significant)
Table 10 : Uric Acid
Uric acid 
at
Group A Group B
‘p’
Mean S.D Mean S.D
Admission 6.56 1.82 5.98 1.35 0.2201 
(Not Significant)
24 hours 5.69 1.19 5.4 1.15 0.1799 
(Not Significant)
Mean serum level of urea, uric acid, creatinine, hemoglobin were not 
significantly different between both groups at 24 hrs.
Table 11 : Duration of Stay in MICU
Group
Duration of stay in MICU 
( in hours)
Mean SD
Group A 55.72 9.57
Group B 69.37 12.6
‘p’ 0.0002 (Significant)
The mean duration of stay in MICU was significantly shortened in 
curettage group compare to non curettage group.
DISCUSSION
Resolution  of  pre  eclampsia  occurs  only  with  delivery  and 
subsequent removal of functioning trophoblastic tissue.  As postulated by 
Rodgers et al and Musci et al, these trophoblastic cells produce  factor that 
is cytotoxic to endothelial cells and in responsible for the multiplicity of 
clinical expression of pre eclampsia pathophysiology.
The  presence  of  a  toxin  that  acts  as  a  pressor  substance  in  the 
deciduas  and  amniotic  fluid  of  patients  with  pre  eclampsia  has  been 
suggested  since  the  work  of  Hunter  and  Howard  in  1960.  The  high 
decidual concentration of this substance, which they called ‘hystrotonin’ 
led these investigators to perform postpartum curettage in 70 women with 
preeclampsia.  After curettage they observed more rapid resolution of the 
elevated blood pressure that accompanied pre eclampsia.
Our study, compared 2 groups of patients with eclampsia.One 
group underwent postpartum curettage and the other had no curettage.
1) Maternal age: In our study, the mean maternal age was 22.64 years in 
the curettage group and 22.94 years in the non curettage group. In the 
study  conducted  by  Samir  Fouad  Abdel  Aziz,  the  mean  age  was 
24.9years  and 25.8 years  in  the  curettage  and non curettage  groups 
respectively.
2) Unbooked cases: 92% were unbooked cases in our study. In the study 
by Bhargava Adarsh et al, 85.7% of the cases were unbooked. Similar 
findings have been reported by Chandra & Bhardwaj. Antenatal care 
plays  a  significant  role  in  early  detection  and  management  of 
preeclampsia and eclampsia.   
3) Parity: 60-72% of  the  cases  were  primigravidae  and  28-40% were 
multigravidae, in our study. In the study by Samir Fouad Abdel Aziz, 
79.2% of the parturient women were primi and 75.9% were multi.
4)  Gestational age: The mean gestational age in our study was 31.84 
weeks in  the curettage group and 34.68 weeks in  the non curettage 
group. In Bhargava Adarsh study it was 32.3 weeks and 33.5 weeks in 
the study and control  group respectively,  similar to  that  reported by 
Magann et al. In  the study by Samir Fouad Abdel Aziz, it was 38.2 
weeks in curettage group compared to 37.9 weeks in the non curettage 
group.
5)  Mode of delivery: The LSCS rate was 20% in the curettage group 
compared to 8% in the control group. This is in gross variance with the 
Bhargava Adarsh  et  al  study  which reported  58% LSCS rate  in  the 
subjects and 68%  LSCS rate in the controls.
6) MAP: On admission, the MAP was 124.4 mm of Hg in the subjects 
and 121 mm of Hg in controls in Bhargava et al, where-as it was 129.5 
mm of Hg and 129.9 mm of Hg in  the study by Samir Fouad Aziz. In 
our study the MAP in curettage and non curettage groups were 118.32 
mm Hg and 123.68 mm Hg respectively.
The MAP of the curettage group was significantly reduced compared 
with the controls at  each 12 hours in all  the above studies with the 
largest difference  at 14 hours (p<0.0002) in Samir Fouad Aziz study; at 
16 hours (p<0.002) in Bhargava Adarsh et al and 24 hours (p<0.0001) 
in our study.
7) Urine  output: Oliguria  is  due  to  reduced  renal  perfusion  and 
glomerular filtration probably resulting from reduced plasma volume. 
Re-establishment of an adequate urinary output is an important priority 
as severe and persistent oliguria may progress to anuria, acute tubular 
necrosis and bilateral cortical necrosis and maternal death.  An earlier 
and  higher  urine  output  in  post  partum  period  leads  to  rapid 
disappearance  of  excessive  extra  vascular  extra  cellular  fluid  and 
edema and thus to accelerated recovery of the disease process.
  Urine output increased following curettage at each of the four intervals 
compared to that observed in the non curettage group. Mean urine output 
was  90.9  ml  in  the  curettage  group  compared  to  72.0  ml  in  the  non 
curettage  group.  The  smallest  difference  between  both  groups  was 
observed at  12 hours and the largest difference at  24 hours postpartum 
(p<0.0001),  in  our  study.  But  the  smallest  and  the  largest  difference 
between both groups was observed in Samir Fouad Aziz study at 4 hours 
and 20 hours respectively (p<0.0002). 
Both these indices, MAP and urine output reflect a more rapid 
resolution of preeclampsia and eclampsia and recovery from the disease 
process presumable via more complete removal of residual trophoblastic 
tissues.
8) Platelets: Circulating platelets were affected by uterine curettage, but 
not significantly.  The curettage group demonstrated an overall mean 
increase  in  platelet  count  from 1.93  lakhs/ml  at  admission  to  2.03 
lakhs/ml at 24 hrs post delivery.  The non curettage group had a mean 
drop in platelet count from 1.87 lakhs/ml at admission to 1.86 lakhs/ml 
at 24 hrs post partum in our study. But the study by Samir Fouad Aziz 
reported  a  significant  change  in  the  platelet  count  with  the 
concentration  increasing  from 1.59  lakhs/ml  to  1.62  lakhs/ml  at  24 
hours postpartum in the curettage group. On contrast, the non curettage 
group  had  a  decreasing  platelet  count  from  1.48  lakhs/ml  to  1.35 
lakhs/ml (p<0.05). Drop in circulating platelets appears to be due to 
increased peripheral destruction produced by residual placental tissue.
More rapid and complete removal of any residual placental tissue after 
delivery  would   theoretically   abort  much  earlier  the  effect  of  any 
factors produced by preeclamptic placental tissue that might directly or 
indirectly lead to peripheral destruction of circulating platelets.
9) Liver function tests and renal function tests: Magann et al found no 
significant difference in liver function and renal function tests at 24 
hours postpartum. In Bhargava et al, values of liver function and renal 
function  tests  in  subjects  recorded  a  more  rapid  reversal  to  normal 
compared  to  those  in  controls.  The  difference  in  liver  and  renal 
function tests was significant at 72 hours. Witlin et al reported uric acid 
levels  more accurately  reflect  the  severity  as  well  as  recovery  from 
eclampsia. In our study liver function , renal function and Hemoglobin 
were not significantly different in both groups. This is in par with the 
study by Samir Fouad Aziz which reported that uric acid, creatinine and 
urea levels were not significantly different in both groups at 24 hours 
post delivery.
Further studies are needed with longer duration to evaluate the effect of 
uterine curettage on these indices.
10)  Hospital  stay: Mean  duration  of  stay  in  MICU  was  significantly 
shortened (52.72 hrs) in curettage group compared to non curettage group 
(69.37hrs), in our study. Hunter et al found an inverse relationship between 
the weight of the curetted deciduas and duration of stay in obstetric ICU. 
Average  duration  of   stay  in  ICU  in  the  study  group  was  51.62  hours 
compared to 84.16 hours in  the control group in Bhargava Adarsh et al study.
SUMMARY
 50 women with eclampsia were selected for study, 25 as curettage 
group and 25 as non curettage group.
 70% of the cases belong to age group 20-24 years
 60-72% of the cases were primi gravida, 28-40% of the cases were 
multi gravida
 In  curettage  group  LSCS  rate  was  20%,  In  non  curettage  group 
LSCS rate was 8%
 The MAP was reduced from 118.3 at admission to 103.6 at 12 hrs 
and  98.6  at  24  hrs  in  the  curettage  group,  while  it  was  slightly 
reduced in the control group. (p value – 0.0001 significant.)
 Rate of urine output increased by 45% in the curettage group while it 
was increased by 20% in the non curettage group at 24 hrs. (p value 
0.0001)
 The mean duration of stay in MICU was 55.72 hrs in curettage group 
compared to prolonged 69.37 hrs in the non curettage group. (p value 
0.0002)
 Platelet  count,  serum  uric  acid,  urea,  creatinine,  Hb%  were  not 
significantly different between both groups at 24 hrs post partum.
 Also  there  was  no  significant  difference  in  the  frequency  of 
medications administered to either groups.
 In curettage group,  none of  the patients  had post  partum fit  after 
delivery.  In  non curettage  group one  patient  had further  fits  after 
delivery. There were no infection and haemorrhagic complications 
from curettage.
CONCLUSION
Immediate  puerperal  uterine  curettage  of  the  parturient  with 
eclampsia appears to accelerate disease recovery with no adverse sequelae.
Further  studies  involving large number of  patients  or  multicentric 
studies  are  needed  to  support  the  accelerated  disease  recovery  with 
immediate postpartum curettage.
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PROFORMA
1. Name :
2. Age :
3. I.P. No. :
4. SEC :
5. Registration : Booked / Unbooked
6. Obstetric table :
7. Period of pregnancy :
8. Date & Time of admission :
9. Date & Time of delivery :
10. Date of Discharge :
11. Other Medical Disorder /
Associated complications :
12. At the time of admission :
BP :
Urine Output :
13. USG
14. H/o AP fits : No.of fits Duration Type   Consciousness BP
15. Drugs given
Magnesium Sulphate
Antihypertensives
Others
16. Labour
Spontaneous
Induced PGE2 Gel    Oxytocin T. Misoprostol
Augmented ARM Oxytocin Both
17. Mode of delivery Vaginal Instrumental Caesarean
18. Curettage Done / Not done
19. Investigation On Admission 24hrs after delivery
Hb%
Urine Alb
Blood Urea
Sr. Creatinine
Sr. Uric acid
Sr. Bilirubin
Platelet count
Fundus
20. BP MAP Urine output Drugs
After delivery
4 hours
8 hours
12 hours
16 hours
20 hours
24 hours
21. Post partum fits
PPH
Residual HT
Other complications
22. Duration of stay in MICU 

